Finally, an interesting approach will be to test the therapeutic potential of S1P2 antagonists in diabetes mellitus type 2 with insulin resistance and progressive β-cell loss, and to see whether atherosclerosis is also attenuated in these patients. Here, S1PR2 is linked to Insulin resistance.